Ajay Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ajay Kumar has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Chandrasekhar Bal
2 shared publicationsDeep N. Srivastava
1 shared publicationDeep Narayan Srivastava
1 shared publicationSanjay Prayagraj Thulkar
1 shared publicationSanjay Sharma
1 shared publicationSiddharta Duttagupta
1 shared publication
Latest Publications
- 1 February 2006
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 18 (2) , 219-223
Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188???HDD-lipiodol
We tried to evaluate the role of dosimetry-guided transarterial radionuclide therapy (TART) with rhenium-188 (Re-188)–4-hexadecyl 1-2, 9, 9-tetramethyl-4, 7-diaza-1, 10-decanethiol (HDD)-lipiodol in a patient with multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma (HCC). The dosimetry helped in delivering the maximum possible activity of Re-188, thus the radiation-absorbed dose, safely to the tumour without jeopardizing other organs. There was no procedure-related complication and the patient tolerated therapy well with no adverse effects. The lesions were completely ablated with a single dose of Re-188 and the patient has been disease free for the past 18 months. TART with Re-188–HDD-lipiodol appears to be a promising therapeutic option in patients with HCC who experience recurrence after percutaneous ablative therapy.
- 1 February 2006
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 18 (2) , 219-223
Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188???HDD-lipiodol
We tried to evaluate the role of dosimetry-guided transarterial radionuclide therapy (TART) with rhenium-188 (Re-188)–4-hexadecyl 1-2, 9, 9-tetramethyl-4, 7-diaza-1, 10-decanethiol (HDD)-lipiodol in a patient with multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma (HCC). The dosimetry helped in delivering the maximum possible activity of Re-188, thus the radiation-absorbed dose, safely to the tumour without jeopardizing other organs. There was no procedure-related complication and the patient tolerated therapy well with no adverse effects. The lesions were completely ablated with a single dose of Re-188 and the patient has been disease free for the past 18 months. TART with Re-188–HDD-lipiodol appears to be a promising therapeutic option in patients with HCC who experience recurrence after percutaneous ablative therapy.
- 1 January 2006
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 17 (1) , 157-161
Management of Postsurgical Recurrence of Hepatocellular Carcinoma with Rhenium 188–HDD Labeled Iodized Oil
- 1 January 2006
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 17 (1) , 157-161
Management of Postsurgical Recurrence of Hepatocellular Carcinoma with Rhenium 188–HDD Labeled Iodized Oil